Date: October 26, 2022
Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST)
In this webinar, attendees will be provided an overview of the technologies that currently exist for bacterial endotoxins testing (BET), and the drawbacks associated with each. Microfluidic technology will be discussed with the intent of educating the audience on the advantages it has over the traditional gel clot/96 well plate methods and how through implementing microfluidic technology, quality control lab testing can be leaned out with respect to LAL testing and sustainability. Attendees will also receive an introduction to the Sievers Eclipse BET Platform to understand why it was created and how it works to simplify and automate endotoxin assay setup, while maintaining full compliance. With Eclipse, compliant 21-sample assays can be set up in as little as 9 minutes, leading to substantial efficiency gains. This webinar will leave attendees with a solid understanding of how the Eclipse platform stacks up next to other technology on the market, and how it can be evaluated and validated in a QC lab to demonstrate viability for routine endotoxin testing.
- An overview of the endotoxin testing technologies that currently exist
- The advantages of microfluidic technology over the traditional method gel clot
- How QC labs can automate and lean out testing with respect to LAL assays and sustainability
- How the Eclipse platform aligns with USP , EP 2.6.14, and JP 4.01
Webinars will be available for unlimited on-demand viewing after live event.